- CelebrityYahoo Celebrity UK
The 10-year-old is the third child Travolta had with his late wife Kelly Preston.
- NewsYahoo Celebrity UK
The mother-of-two lost her life on Saturday 21 November while attempting to get a look at the castle's lights, her family have said.
- PoliticsThe Independent
In the end, the president who roared like a lion went out with a whimper. Those who have followed him knew it would end this way, writes Washington Bureau Chief John T. Bennett
- NewsYahoo News UK
Paul Fitzgerald, 30, who murdered Richard Huckle laughed throughout his sentencing hearing as he was jailed for life.
- BusinessThe Telegraph
Live updates: FTSE rises as vaccine optimism boosts markets Analysis: How AstraZeneca went from takeover target to FTSE winner Shares in AstraZeneca closed down almost 4pc as investors were left disappointed by an update on its coronavirus vaccine trial and one analyst claimed the vaccine would not win approval from US regulators. A progress report on the clinical trial, which is still ongoing, suggests the vaccine being trialled with Oxford University is 70pc effective on average in preventing coronavirus. This is less than the 90pc efficacy rates reported by US vaccine hopefuls Moderna and Pfizer over the past two weeks. Investors were also spooked after a US-based analyst questioned the trial results in a note to investors and said the vaccine would not get the FDA nod. However, other analysts were quick to rebut his claims, saying it was too early to make a call and that much clinical trial data on all three vaccines still needed to be analysed. “Far be it from me to dispute one of my peers or competitors but I think it’s too early for me or anyone, in fact, to be making a statement on regulatory approval,” said one analyst. “None of us have seen the full data for one, let alone all trials. Comparing apples and pears at this stage is a little misleading.” Asked about the note, Ruud Dobber, head of AstraZeneca’s biopharmaceuticals business unit, told Bloomberg TV: “I think it’s far too early to speculate about how regulators will react.” AstraZeneca said the vaccine had no serious side effects and that trial had shown a smaller dose, followed by a full dose, had an efficacy rate of 90pc.